The prospects of minocycline in multiple sclerosis
Authors:
- Xiaohong ChenXCXiaohong Chen
- Xiaomeng MaXMXiaomeng Ma
- Ying JiangYJYing Jiang
- Rongbiao PiRPRongbiao Pi
- Yingying LiuYLYingying Liu
- Lili MaLMLili Ma
- 1 June 2011
- journal article
- review article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 235 (1-2) , 1-8
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Minocycline Prevents Osmotic Demyelination Syndrome by Inhibiting the Activation of MicrogliaJournal of the American Society of Nephrology, 2010
- Improving Outcomes of Neuroprotection by MinocyclineThe American Journal of Pathology, 2010
- NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trialThe Lancet Neurology, 2009
- PEG Minocycline-Liposomes Ameliorate CNS Autoimmune DiseasePLOS ONE, 2009
- Minocycline and neurodegenerative diseasesBehavioural Brain Research, 2009
- Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitisExperimental Neurology, 2008
- Interferons in multiple sclerosis: Ten years' experienceBiochimie, 2007
- Inhibitory action of minocycline on lipopolysaccharide-lnduced release of nitric oxide and prostaglandin E2 in BV2 microglial cellsArchives of Pharmacal Research, 2004
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- The influence of tetracyclines on T cell activationClinical and Experimental Immunology, 1995